Bleomycin.
Bleomycin was approved by the Food and Drug Administration in 1975 for therapy against squamous cell carcinomas, testicular cancers, and malignant lymphomas. An extensive bibliography on this drug indicates that there is little evidence of activity against other malignancies. Although initially used exclusively as a single agent, bleomycin has been considered recently for use in combination chemotherapy. Because of associated toxicity involving the lung and mucous membranes, bleomycin should be used cautiously by physicians, particularly in noninvestigational settings.
D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002626:Chemistry, Pharmaceutical; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D008168:Lung / Q000187:drug effects; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D009092:Mucous Membrane / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy*; D013736:Testicular Neoplasms / Q000188:drug therapy
D001761:Bleomycin